AMAG Pharmaceuticals — Investor Presentation (April 2014)
27 slides from AMAG Pharmaceuticals's investor presentation, Apr 9, 2014
Slide 1: AMAG Pharmaceuticals April 2014
AMAG Pharmaceuticals April 2014 AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES.
Slide 2: Forward Looking Statements
Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, state
Slide 3: AMAG: Building a Multi-Product Specialty Pharmaceutical Company
AMAG today: Two revenue-generating commercial products Feraheme® : a differentiated intravenous iron for treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) MuGard®: prescription oral mucoadhesive rinse for the management of oral mucositis Established commer
Slide 4: AMAG: Positioned for Accelerated Growth
AMAG: Positioned for Accelerated Growth Past (2010-2011) Present (2012 - 2013) Future Products Single product Two products Diversified Portfolio Low/no growth Double-digit growth Strong CAGR Price deterioration Price appreciation Price optimization Feraheme Gross Margin ~75% ~83% Significant gross m
Slide 5: Growing: Drive revenue growth by optimizing performance of Feraheme
GROWING Drive revenue growth by optimizing the performance of Feraheme
Slide 6: Feraheme: 1–2–3
Feraheme: 1–2–3 5 1 One gram of IV iron is the usual therapeutic course and that which was studied in the Feraheme clinical trials. Feraheme Indication and Contraindications: Feraheme ® (ferumoxytol) Injection for Intravenous (IV) is indicated for the treatment of iron deficiency anemia in adult pat
Slide 7: Feraheme Performance
Feraheme Performance 6 Net ex-factory sales* ($ in millions) 2012 vs 2011 +12% growth (+17% volume, -5% price) * Excludes the impact of changes in estimates made to product returns and Medicaid reserves in 2012 and 2013 Net Sales 2013 vs 2012 +28% growth (+22% volume, +6% price) Copyright © 2014 AMA
Slide 8: U.S. IV Iron Market: Competitive Landscape
U.S. IV Iron Market: Competitive Landscape 7 *Aggregate of Ferrlecit Brand + Generic Ferric Gluconate Source: IMS DDD Data thru week ending 12/20/13 2013 Share of ~850,000 Gram Non-dialysis Market Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.
Slide 9: Today's Commercial Objective: Increase Share of Current CKD IV Iron Market
Today’s Commercial Objective: Increase Share of Current CKD IV Iron Market 8 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes an
Slide 10: 2014: U.S. IDA Label Expansion
2014: U.S. IDA Label Expansion 9 *If regulatory approval is pursued and received. Complete response letter (CRL) received Evaluate CRL and develop responsive and economically viable proposal Meet with FDA to discuss proposal and other possible approaches to address the points raised in CRL sNDA subm
Slide 11: Potential IDA Label Expansion: Gain Additional Share of IV Iron Market
10 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010: 41-42; Fishbane, S. e
Slide 12: Opportunity: Grow U.S. IV Iron Market
Opportunity: Grow U.S. IV Iron Market 11 IV Iron IDA* IV Iron IDA-CKD 4,000,000 patients diagnosed with IDA placed on oral iron therapy IV Iron IDA-CKD IV Iron IDA* Oral Iron IDA* Oral Iron IDA-CKD *If regulatory approval is pursued and received. 4,000,000 patients diagnosed with IDA placed on oral
Slide 13: Takeda in Europe
Takeda’s in Europe 12 Double-digit tiered royalties on Takeda sales Additional potential milestones Ferumoxytol is marketed under the Rienso trade name in EU Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. 2010 $60 million upfront paid for select international markets 2012 $33 milli
Slide 14: Building: Build our future by expanding our product portfolio
BUILDING Build our future by expanding our product portfolio
Slide 15: Building a Profitable, Multi-product Specialty Pharmaceutical Company
Building a Profitable, Multi-product Specialty Pharmaceutical Company Commercial Infrastructure Focus on Hematology/Oncology, Hospital and Nephrology Strong Balance Sheet Experienced Management Team Feraheme® U.S. CKD Business Feraheme IDA label Expansion* IV Iron Market Expansion Feraheme Geographi
Slide 16: MuGard: >$500 Million Market Opportunity
MuGard: >$500 Million Market Opportunity In-licensed in 2013; $3.3 million upfront license fee MuGard: the only oral mucositis product that forms a protective coating over the oral mucosa to shield the membranes of the mouth and tongue MuGard $1,500/Rx (50% price increase April 1st) 15 < 5% Currentl
Slide 17: MuGard's Road to Success in 2014
MuGard’s Road to Success in 2014 16 MuGard is a prescription oral rinse for the management of oral mucositis Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Strategies for Success in 2014 Differentiate MuGard Distinguish muco-adhesive from oral rinses Physician Targeting Sub-segment
Slide 18: Targeted Business Development: Fact #1
Targeted Business Development 17 Bulls-Eye Hem/onc or hospital company or product $10 MM–$60 MM/yr. revenue potential IP runway Immediately accretive ~130 branded specialty products with revenues between $10MM and $50MM Fact #1 Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.
Slide 19: Targeted Business Development: Fact #2
Targeted Business Development 18 Strategic Opportunities aligned with Feraheme growth strategy Gastroenterology, rheumatology, women’s health ~90 branded specialty products with revenues between $51MM and $100MM Bulls-Eye Hem/onc or hospital company or product $10 MM–$60 MM/yr. revenue potential IP
Slide 20: Targeted Business Development: Fact #3
Targeted Business Development 19 Financial Similarly sized specialty company Eliminate overlapping infra- structure and increase EBITDA Examine transactions to optimize after-tax cash flows ~ 75 small private companies with U.S. marketed specialty products Strategic Opportunities aligned with Ferahe
Slide 21: Examples of Successfully Executing a Build Strategy
Examples of Successfully Executing a Build Strategy 20 Industry peers have utilized business development to broaden their portfolios and reduce dependence on a single commercial product Oritavancin FibroCapsTM IONSYSTM Cangrelor Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.
Slide 22: 2014 Outlook
2014 OUTLOOK
Slide 23: Key Financial Metrics: Positive Trends 2011 - 2014
Key Financial Metrics: Positive Trends 2011 - 2014 22 Revenues ($ in millions) Expenses ($ in millions) Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.
Slide 24: 2014 Financial Outlook
2014 Financial Outlook ($ in millions) Projections* Change from 2013 (calculated at midpoint of 2014 range) Total revenues $88 - $100 +16% U.S. Feraheme sales, net $75 - $85 +12% Feraheme COGS (% of Feraheme global net sales) 14% - 16% -12% Operating expenses $80 - $85 +3% Cash and investments $392
Slide 25: 2014 Goals
2014 Goals Maximize Feraheme opportunities Drive market share and market growth within current U.S. IDA-CKD indication Optimize net revenue per gram Potential label expansion: IDA (non-CKD) oral iron failures Expected E.U. action – mid-2014; broad IDA approval triggers significant milestone Determin
Slide 26: Well positioned for success in 2014... and beyond
Well positioned for success in 2014. . . and beyond. AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES.
Slide 27: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation 26 ($ in millions) 2013 2014 (est.) Net loss ($9.6) ($15.7) Interest expenses $5.0 Amortization of debt discount and deferred financing costs $ - $10.7 Sub-total ($9.6) $ - Fair value adjustment to contingent consideration expense $1.1 $2.3 Depreciation & amortization
AMAG Pharmaceuticals — Investor Presentation (April 2014) on 6ix